Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 16/20 | 0.73 |
| ▸ | GRIN2B | Q13224 | 16/20 | 0.73 |
| ▸ | RXRA | P19793 | 13/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19211426 | 0.90 | GRIN1 (0.71) | GRIN1GRIN2BRXRAKCNH2CYP1A2 | |
| SCHEMBL19211446 | 0.88 | GRIN1 (0.72) | GRIN1GRIN2BRXRAKCNH2CYP1A2 | |
| SCHEMBL19221891 | 0.86 | GRIN1 (0.65) | GRIN1GRIN2BRXRAKCNH2CYP1A2 | |
| SCHEMBL19219191 | 0.85 | GRIN1 (1.00) | GRIN1GRIN2BRXRAKCNH2 | |
| SCHEMBL17502332 | 0.84 | KCNH2 (1.00) | GRIN1GRIN2BRXRAKCNH2CYP1A2 | |
| SCHEMBL17502250 | 0.84 | KCNH2 (1.00) | GRIN1GRIN2BRXRAKCNH2CYP1A2 | |
| SCHEMBL17502279 | 0.83 | RXRA (0.64) | GRIN1GRIN2BRXRAKCNH2 | |
| SCHEMBL19211324 | 0.82 | GRIN1 (0.76) | GRIN1GRIN2BRXRAKCNH2 | |
| SCHEMBL19219165 | 0.82 | GRIN1 (1.00) | GRIN1GRIN2BRXRAKCNH2 | |
| SCHEMBL19219178 | 0.81 | GRIN1 (1.00) | GRIN1GRIN2BRXRAKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9981950-B2 | Triazoles as NR2B receptor inhibitors | Janssen Pharmaceuticals, Inc. (US) | 2018-05-29 | — | — | US | disclosed |
| US-20170226087-A1 | TRIAZOLES AS NR2B RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICALS INC (US) | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226087-A1 | TRIAZOLES AS NR2B RECEPTOR INHIBITORS | GRIN2B, GRIN1, GRIN3A | GRIN1 2/4885GRIN2B 1/4885RXRA 1823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.